At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NRXS Neuraxis, Inc.
Market Closed 12-12 16:00:00 EST
2.65
+0.02
+0.76%
盘后2.65
+0.000.00%
16:44 EST
High2.78Low2.65Vol40.12K
Open2.65D1 Closing2.63Amplitude4.94%
Mkt Cap28.23MTradable Cap20.32MTotal Shares10.65M
T/O108.80KT/O Rate0.52%Tradable Shares7.67M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

NeurAxis Secures VA Federal Supply Schedule Contract for IB-Stim
Reuters  ·  12-01
NeurAxis Secures VA Federal Supply Schedule Contract for IB-Stim
Neuraxis Inc: Co Expects Va Award to Support Sustained Commercial Momentum Entering 2026
THOMSON REUTERS  ·  12-01
Neuraxis Inc: Co Expects Va Award to Support Sustained Commercial Momentum Entering 2026
Neuraxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients With Functional Abdominal Pain
THOMSON REUTERS  ·  12-01
Neuraxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients With Functional Abdominal Pain
Neuraxis announces new medical policy coverage in Michigan
TIPRANKS  ·  11-12
Neuraxis announces new medical policy coverage in Michigan
NeurAxis, Inc. Earnings Call: Growth Amid Challenges
TIPRANKS  ·  11-12
NeurAxis, Inc. Earnings Call: Growth Amid Challenges
NeurAxis Inc. reports third quarter revenue up 22% to $811,000
Reuters  ·  11-11
NeurAxis Inc. reports third quarter revenue up 22% to $811,000
Press Release: NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues
Dow Jones  ·  11-11
Press Release: NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues
Neuraxis Q3 EPS $(0.24) Misses $(0.17) Estimate, Sales $811.414K Miss $1.000M Estimate
Benzinga  ·  11-11
Neuraxis Q3 EPS $(0.24) Misses $(0.17) Estimate, Sales $811.414K Miss $1.000M Estimate
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), NeurAxis, Inc. (NRXS) and Celcuity (CELC)
TIPRANKS  ·  11-10
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), NeurAxis, Inc. (NRXS) and Celcuity (CELC)
NeurAxis Inc. to Release Third Quarter 2025 Results
Reuters  ·  11-04
NeurAxis Inc. to Release Third Quarter 2025 Results
Neuraxis received FDA 510k clearance for PENFS technology
TIPRANKS  ·  10-24
Neuraxis received FDA 510k clearance for PENFS technology
NeurAxis Wins FDA Clearance for First Adult Functional Dyspepsia Pain Device
Reuters  ·  10-24
NeurAxis Wins FDA Clearance for First Adult Functional Dyspepsia Pain Device
Neuraxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) With Associated Nausea Symptoms in the Adult Patient Population
THOMSON REUTERS  ·  10-24
Neuraxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) With Associated Nausea Symptoms in the Adult Patient Population
NeurAxis Inc. reports $0.8 million net sales and $2.1 million operating loss for Q3 2025
Reuters  ·  10-24
NeurAxis Inc. reports $0.8 million net sales and $2.1 million operating loss for Q3 2025
Craig-Hallum Reaffirms Their Buy Rating on NeurAxis, Inc. (NRXS)
TIPRANKS  ·  09-25
Craig-Hallum Reaffirms Their Buy Rating on NeurAxis, Inc. (NRXS)
NeurAxis Inc. Announces $3.3 Million At-The-Market Offering Agreement with Craig-Hallum Capital
Reuters  ·  09-02
NeurAxis Inc. Announces $3.3 Million At-The-Market Offering Agreement with Craig-Hallum Capital
Neuraxis Q2 EPS $(0.22) Beats $(0.23) Estimate, Sales $894.086K Miss $967.250M Estimate
Benzinga  ·  08-12
Neuraxis Q2 EPS $(0.22) Beats $(0.23) Estimate, Sales $894.086K Miss $967.250M Estimate
NeurAxis Inc. Q2 2025: Revenues Surge 46%, Operating Loss Improves by 22%
Reuters  ·  08-12
NeurAxis Inc. Q2 2025: Revenues Surge 46%, Operating Loss Improves by 22%
Masimo Corp Reports Disposal of Common Shares of NeurAxis Inc
Reuters  ·  07-04
Masimo Corp Reports Disposal of Common Shares of NeurAxis Inc
BRIEF-Neuraxis Terminates License Agreement With Masimo
Reuters  ·  07-04
BRIEF-Neuraxis Terminates License Agreement With Masimo

Introduction

Company Name.
Neuraxis, Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. NeurAxis, Inc. was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is based in Versailles, Indiana.
Issue price:
--